Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Delayed Quote. Delayed London Stock Exchange - 10/21 11:35:10 am
8863 GBX   +1.08%
10/21VC DAILY : ShouTi Lands $100 Million to Develop -2-
10/21ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns
10/21ASTRAZENECA : JP Morgan reaffirms its Buy rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing

07/30/2021 | 10:42am EDT
FILE PHOTO: A woman holds a test tube in front of displayed Emergent logo in this illustration

WASHINGTON, July 30 (Reuters) - Drug manufacturer Emergent BioSolutions Inc said on Friday it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.

Emergent came under regulatory scrutiny after an error led to millions of vaccine doses being ruined at its manufacturing facility in Baltimore, which was producing bulk drug substance for Johnson & Johnson's COVID-19 vaccine.

The U.S. Food and Drug Administration (FDA) in April halted operations at the plant after it discovered that ingredients from AstraZeneca's COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.

Emergent in a filing https://investors.emergentbiosolutions.com/node/20661/html on Friday said it has received "preliminary inquiries and subpoenas to produce documents" from the lawmakers, the Department of Justice, the Securities and Exchange Commission, the Financial Industry Regulatory Authority, and Maryland and New York Attorneys General.

The Department of Justice declined to comment on the matter.

Emergent said it was producing and has produced documents as required in response and will continue to cooperate with the government inquiries.

An FDA inspection in April turned up a long list of sanitary problems and bad manufacturing practices at the facility, including failure to train personnel to avoid cross contamination of COVID-19 vaccines from J&J and AstraZeneca.

Emergent said on Wednesday production at the Baltimore facility will now resume, following remedial actions, additional reviews and collaboration with the FDA and its manufacturing partners.

An FDA spokesperson said on Thursday the facility has not yet received any authorization for a COVID-19 vaccine, but may produce vaccine substance in advance of future inspections by the health regulator. (Reporting by Chris Prentice in Washington and Manojna Maddipatla in Bengaluru; Editing by Bernard Orr and Shounak Dasgupta)

© Reuters 2021
All news about ASTRAZENECA PLC
10/21VC DAILY : ShouTi Lands $100 Million to Develop -2-
10/21ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns
10/21ASTRAZENECA : JP Morgan reaffirms its Buy rating
10/20ASTRAZENECA : Credit Suisse remains its Buy rating
10/20ASTRAZENECA : Announces Winners and Recognizes Oncology Change Makers in Third Annual Canc..
10/20ASTRAZENECA : Air Malta Transports Maltese Solidarity to Rwanda; 135,690 AstraZeneca vacci..
10/20KAROLINSKA INSTITUTET : Two COVID-19 Vaccine Doses Increase Airway Antibodies After Infect..
10/20MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
10/20ASTRAZENECA : Conference Chair Di Morris, AstraZeneca Invites You to Join SMi's 10th Annua..
10/20LONDON STOCK EXCHANGE : Nearly half of FTSE 100 companies have no net-zero target, Arabesq..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 441 M - -
Net income 2021 4 862 M - -
Net Debt 2021 24 847 M - -
P/E ratio 2021 35,4x
Yield 2021 2,31%
Capitalization 189 B 190 B -
EV / Sales 2021 6,04x
EV / Sales 2022 4,89x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 122,23 $
Average target price 137,81 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC21.01%189 570
JOHNSON & JOHNSON3.83%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.16.27%239 966
NOVO NORDISK A/S56.26%238 738